STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
At today’s Extraordinary General Meeting in Karo Pharma the following main resolutions were passed
The meeting resolved in accordance with the board´s proposal for a resolution to issue stock options and to implement an option plan for personnel
The resolution concerns an issue of maximum 5,200,000 options. The right to subscribe for the options shall, with deviation from the shareholders´ preferential rights, be vested in Karo Pharma AB's wholly owned subsidiary Karo Pharma Research AB, reg. no. 556588-3641, (the "Subsidiary"), which will offer personnel in Karo Pharma Group to acquire such options.
Subscription for options shall take place no later than August 26 2016. The options will be issued to the Subsidiary against no remuneration.
Each option entitles the holder to subscribe for one new share in the company. The subscription price shall be an amount equivalent to twice the volume weighted average price of the Karo Pharma share during the period between August 1, 2016 and August 12, 2016, though not below the par value.
The right to acquire share options from the Subsidiary shall be granted to personnel in the Karo Pharma Group, whereby the company's executive chairman and the executive group shall be entitled to acquire 4,200,000 options.
At full subscription for new shares with the support of all options the share capital will be increased by approximately SEK 2,079,977.10 which corresponds to a dilution of approximately 7.5% of the share capital and votes.
About Karo Pharma
Karo Pharma is a health care company focused on developing and marketing of products to pharmacies, fast-moving consumer goods and the fealth care directly. Karo Pharma is listed on Nasdaq Stockholm.
Karo Pharma publishes this information in accordance with the Swedish Securities Markets Act. The information was submitted for publication on July 21, 2016, at 7:00 pm CET
This press release is also available at www.karopharma.com and www.newsroom.cision.com (http://www.newsroom.cision.com)
This information was brought to you by Cision http://news.cision.com